This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-25. Anything still debated is marked as such rather than presented as settled.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
=== Microbead-based immobilization === Microbead-based immobilization is a modular technique in that it allows the investigator to decide whether they wish to fish for protein targets from the proteome or drug-like compounds from chemical libraries. The macroscopic properties of microbeads make them amenable to relatively low labor enrichment applications, since they are easily to visualize and their bulk mass is readily removable protein solutions. Microbeads were historically made of inert polymers, such as agarose and dextran, that are functionalized to attach a bait of choice. In the case of using proteins as bait, amine functional groups are common linkers to facilitate attachment. More modern approaches have benefitted from the popularization of dynabeads, a type of magnetic microbead, which enable magnetic separation of bead-immobilized analytes from treated samples. Magnetic beads exhibit superparamagnetic properties, which make them very easy to remove from solution using an external magnet. In a simplified workflow, magnetic beads are used to immobilize a protein target, then the beads are mixed with a chemical library to screen for potential ligands. High-affinity ligands bind to the immobilized target and resist removal by washing, so they are enriched in the sample. Conversely, a ligand of interest can be immobilized and screened against proteome proteins by incubation with a lysate.
The MIM mode, on the other hand will usually employ a much longer dwell time on each ion, and as a result, accurate quantification is possible to the parts per billion (ppb) level. SIFT-MS utilises an extremely soft ionisation process which greatly simplifies the resulting spectra and thereby facilitates the analysis of complex mixtures of gases, such as human breath. Another very soft ionization technique is secondary electrospray ionization (SESI-MS). For example, even proton-transfer-reaction mass spectrometry (PTR-MS), another soft ionisation technology that uses the H3O+ reagent ion, has been shown to give considerably more product ion fragmentation than SIFT-MS. Another key feature of SIFT-MS is the upstream mass quadrupole, which allows the use of multiple precursor ions. The ability to use three precursor ions, H3O+, NO+ and O2+, to obtain three different spectra is extremely valuable because it allows the operator to analyse a much wider variety of compounds. An example of this is methane, which cannot be analysed using H3O+ as a precursor ion (because it has a proton affinity of 543.5kJ/mol, somewhat less than that of H2O), but can be analysed using O2+. Furthermore, the parallel use of three precursor ions may allow the operator to distinguish between two or more compounds that react to produce ions of the same mass-to-charge ratio in certain spectra. For example, dimethyl sulfide (C2H6S, 62 amu) accepts a proton when it reacts with H3O+ to generate C2H7S+ product ions which appear at m/z 63 in the resulting spectrum.
Nationalist movements in some countries and regions, notably Guatemala, Indonesia and Indochina, were often allied with Communist groups or otherwise perceived to be unfriendly to Western interests. In this context, the United States and the Soviet Union increasingly competed for influence by proxy in the Third World as decolonization gained momentum in the 1950s and early 1960s. Both sides were selling armaments to gain influence. The Kremlin saw continuing territorial losses by imperial powers as presaging the eventual victory of their ideology. The United States used the Central Intelligence Agency (CIA) to undermine neutral or hostile Third World governments and to support allied ones. In 1953, President Eisenhower implemented Operation Ajax, a covert coup operation to overthrow the Iranian prime minister, Mohammad Mosaddegh. The popularly elected Mosaddegh had been a Middle Eastern nemesis of Britain since nationalizing the British-owned Anglo-Iranian Oil Company in 1951. Winston Churchill told the United States that Mosaddegh was "increasingly turning towards Communist influence." The pro-Western shah, Mohammad Reza Pahlavi, assumed control as an autocratic monarch. The shah's policies included banning the communist Tudeh Party of Iran, and general suppression of political dissent by SAVAK, the shah's domestic security and intelligence agency. In Guatemala, a banana republic, the 1954 Guatemalan coup d'état ousted the left-wing President Jacobo Árbenz with material CIA support.
Sources: en.wikipedia.org
The neurotransmitter serotonin, a non-selective serotonin receptor agonist, strongly increases oxytocin levels, by up to 12-fold, when given via intracerebroventricular injection in rodents. This can be blocked by various serotonin receptor antagonists. Selective serotonin 5-HT1A receptor agonists like 8-OH-DPAT, buspirone, and ipsapirone increase oxytocin levels in rodents. Both 8-OH-DPAT and buspirone maximally increased oxytocin levels by around 9-fold, whereas ipsapirone increased oxytocin levels by only around 3-fold. Similarly to serotonin 5-HT1A receptor agonists, the serotonin 5-HT2 receptor agonist DOI increases oxytocin levels in rodents, with a maximal increase of around 5- to 10-fold depending on the dose. The serotonin 5-HT2A receptor antagonist ketanserin reduced the increase in oxytocin levels induced by DOI by about 90%, while addition of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor antagonist LY-53857 fully blocked the increase. The non-selective but preferential serotonin 5-HT2C receptor agonist meta-chlorophenylpiperazine (mCPP) maximally increased oxytocin levels by around 6-fold, with the increases minimally affected by ketanserin but abolished by non-selective serotonin 5-HT2 receptor antagonists including LY-53857, mianserin, and metergoline. Another non-selective but preferential serotonin 5-HT2C receptor agonist, MK-212, robustly increases oxytocin levels in rodents as well. The serotonin 5-HT3 receptor agonists SR-57277 and m-CPBG and the serotonin 5-HT4 receptor agonist RS-67506 increase oxytocin levels maximally by several-fold in rodents.
== External links == http://www.apsciences.com http://www.invitroadmet.com "Scientist shows the way to take guinea pigs off lab," Karthika Gopalakrishnan. The Times of India. 17 February 2011. Retrieved 19 August 2015.
=== X rays === X-ray equipment, like CAT scans, are used to study the interior of fossil eggs. Unlike CAT scans, x-ray imaging condenses the entire interior of the egg into a single two-dimensional image rather than a series of images documenting the interior in three dimensions. X-ray imaging in the context of dinosaur research has generally been used to look for evidence of embryonic fossils contained inside the egg. However, as of Kenneth Carpenter's 1999 book Eggs, Nests, and Baby Dinosaurs, all putative embryos discovered using x-rays have been misidentifications. This is because the use of x-rays to find embryos is conceptually flawed. Embryo bones are incompletely developed and will generally lack their own mineral content, as such the only source of minerals for these bones is the sediment that fills the egg after burial. The fossilized bones will therefore have the same density as the sediment filling the interior of the egg which served as the source for their mineral content and will be poorly visible in an x-ray image. So far the only reliable method for examining embryonic fossils preserved in dinosaur eggs is to physically extract them through means such as acid dissolution. X-rays can be used to chemically analyze dinosaur eggshell. This technique requires pure shell samples, so the fossil must be completely free of its surrounding rock matrix. The shell must then be further cleaned by an ultrasonic bath. The sample can then be bombarded by electrons emitted by the same sort of probe used by scanning electron microscopes.
The Kennedy administration continued seeking ways to oust Castro following the Bay of Pigs invasion, experimenting with various ways of covertly facilitating the overthrow of the Cuban government. Significant hopes were pinned on the program of terrorist attacks and other destabilization operations known as Operation Mongoose, that was devised under the Kennedy administration in 1961. Khrushchev learned of the project in February 1962, and preparations to install Soviet nuclear missiles in Cuba were undertaken in response. Alarmed, Kennedy considered various reactions. He ultimately responded to the installation of nuclear missiles in Cuba with a naval blockade, and he presented an ultimatum to the Soviets. Khrushchev backed down from a confrontation, and the Soviet Union removed the missiles in return for a public American pledge not to invade Cuba again as well as a covert deal to remove US missiles from Turkey. The Cuban Missile Crisis (October – November 1962) brought the world closer to nuclear war than ever before. The aftermath led to efforts in the nuclear arms race at nuclear disarmament and improving relations, although the Cold War's first arms control agreement, the Antarctic Treaty, had come into force in 1961. The compromise embarrassed Khrushchev and the Soviet Union because the withdrawal of US missiles from Italy and Turkey was a secret deal between Kennedy and Khrushchev, and the Soviets were seen as retreating from circumstances that they had started. In 1964, Khrushchev's Kremlin colleagues managed to oust him, but allowed him a peaceful retirement.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.